| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Achilles Anagnostopoulos | Q42933010 |
| P2093 | author name string | Eleni Gavriilaki | |
| Dimitrios C Mastellos | |||
| P2860 | cites work | Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome | Q24337607 |
| Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype | Q24613907 | ||
| Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura | Q24614077 | ||
| Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome | Q24653523 | ||
| Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome | Q24685473 | ||
| Eculizumab in severe Shiga-toxin-associated HUS | Q28238525 | ||
| Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis | Q28239591 | ||
| Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome | Q28243693 | ||
| Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome | Q28283865 | ||
| A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS) | Q28661698 | ||
| Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort | Q28741729 | ||
| Complement: a key system for immune surveillance and homeostasis | Q29615484 | ||
| A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease | Q30442039 | ||
| Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis | Q30582298 | ||
| Regulation of C3a receptor signaling in human mast cells by G protein coupled receptor kinases | Q31028372 | ||
| The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. | Q33337105 | ||
| Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura | Q33338776 | ||
| Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma | Q33359551 | ||
| Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. | Q33364613 | ||
| The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts | Q33365530 | ||
| Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation | Q33366979 | ||
| Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation | Q33367451 | ||
| von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation | Q33370723 | ||
| Heme interacts with c1q and inhibits the classical complement pathway | Q34963775 | ||
| Pre-eclampsia: pathophysiology, diagnosis, and management | Q35141777 | ||
| Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention | Q35236103 | ||
| Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity | Q35685660 | ||
| Antigen-presenting cell-derived complement modulates graft-versus-host disease | Q36005386 | ||
| Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. | Q36219724 | ||
| Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. | Q36405585 | ||
| Complement, a target for therapy in inflammatory and degenerative diseases. | Q38614302 | ||
| Heme: Modulator of Plasma Systems in Hemolytic Diseases | Q38732762 | ||
| The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes. | Q38758239 | ||
| Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4. | Q38886279 | ||
| Complementopathies | Q39142842 | ||
| Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation | Q39229604 | ||
| Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. | Q39246952 | ||
| Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. | Q39307644 | ||
| Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD. | Q39982138 | ||
| Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation - a Comparison of Eculizumab Therapy and Conventional Therapy | Q40071991 | ||
| Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact. | Q40448379 | ||
| Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex | Q40489320 | ||
| Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria | Q40559071 | ||
| Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak. | Q40652002 | ||
| Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination. | Q40722182 | ||
| Loss of DGKε induces endothelial cell activation and death independently of complement activation | Q41700443 | ||
| Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. | Q44272977 | ||
| Decreased cold-insoluble globulin in congenital thrombocytopenia (Upshaw-Schulman syndrome) | Q44561984 | ||
| Risk factors, management, and outcomes of hemolysis, elevated liver enzymes, and low platelets syndrome and elevated liver enzymes, low platelets syndrome | Q44577112 | ||
| Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy | Q45804466 | ||
| Genetic Susceptibility to Hemolytic-Uremic Syndrome after Shiga Toxin-Producing Escherichia Coli (STEC) Infection: a Centers for Disease Control and Prevention (CDC) FoodNet Study. | Q46030044 | ||
| Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation | Q33371965 | ||
| Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group | Q33373889 | ||
| Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains | Q33375335 | ||
| Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis | Q33382787 | ||
| Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria | Q33384578 | ||
| Thrombomodulin mutations in atypical hemolytic-uremic syndrome | Q33385474 | ||
| Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning | Q33386036 | ||
| Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006. | Q33386636 | ||
| DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome | Q33388274 | ||
| Genetics and complement in atypical HUS. | Q33389945 | ||
| Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group | Q33390678 | ||
| Plasmatherapy in atypical hemolytic uremic syndrome | Q33392018 | ||
| Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome | Q33394691 | ||
| Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy | Q33395413 | ||
| Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. | Q33396969 | ||
| Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. | Q33398635 | ||
| A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function | Q33399198 | ||
| Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae | Q33400221 | ||
| Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study | Q33402456 | ||
| Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice | Q33403090 | ||
| Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies | Q33403607 | ||
| Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis | Q33403897 | ||
| Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry | Q33404151 | ||
| Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? | Q33404805 | ||
| Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults | Q33405246 | ||
| Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype | Q33406025 | ||
| Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome | Q33407898 | ||
| Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome | Q33408211 | ||
| Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies | Q33408216 | ||
| Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy | Q33408788 | ||
| Diagnosis and management of complement mediated thrombotic microangiopathies | Q33413376 | ||
| Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? | Q33414109 | ||
| Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases | Q33414142 | ||
| Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. | Q33414383 | ||
| Genetics of atypical hemolytic uremic syndrome (aHUS). | Q33415087 | ||
| Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults | Q33415603 | ||
| Dynamics of complement activation in aHUS and how to monitor eculizumab therapy | Q33416519 | ||
| Syndromes of thrombotic microangiopathy | Q33417044 | ||
| Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome | Q33419554 | ||
| Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome | Q33419905 | ||
| Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. | Q33420170 | ||
| Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies | Q33420172 | ||
| Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. | Q33421669 | ||
| Atypical aHUS: State of the art. | Q33421720 | ||
| An international consensus approach to the management of atypical hemolytic uremic syndrome in children | Q33421861 | ||
| Modified Ham test for atypical hemolytic uremic syndrome | Q33421884 | ||
| A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience | Q33422224 | ||
| Mechanism of Platelet Activation and Hypercoagulability by Antithymocyte Globulins (ATG). | Q33422771 | ||
| Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome. | Q33423371 | ||
| Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. | Q33426602 | ||
| Complement in hemolytic anemia | Q33427662 | ||
| Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation | Q33429735 | ||
| Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome | Q33430035 | ||
| Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome | Q33430320 | ||
| Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial | Q33431023 | ||
| Defining the genetics of thrombotic microangiopathies | Q33432223 | ||
| Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome | Q33436512 | ||
| Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. | Q33436972 | ||
| Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy | Q33484095 | ||
| Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. | Q33499130 | ||
| Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura | Q33502070 | ||
| Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H | Q33668640 | ||
| Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome | Q33783126 | ||
| The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification | Q33864822 | ||
| Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. | Q34370940 | ||
| Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. | Q34393266 | ||
| Paroxysmal nocturnal hemoglobinuria | Q34431429 | ||
| Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child | Q34516456 | ||
| Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation | Q46159176 | ||
| Eculizumab for the treatment of preeclampsia/HELLP syndrome | Q46321630 | ||
| Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia | Q46377642 | ||
| The renaissance of complement therapeutics. | Q47336749 | ||
| Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults | Q48255838 | ||
| Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. | Q51213973 | ||
| Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. | Q51741449 | ||
| Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. | Q51783073 | ||
| Pregnancy-induced atypical haemolytic uremic syndrome: A new era with eculizumab. | Q52595152 | ||
| Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. | Q52676485 | ||
| Von Willebrand factor regulates complement on endothelial cells. | Q52866918 | ||
| Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. | Q52875784 | ||
| A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. | Q53598537 | ||
| Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases. | Q54306708 | ||
| Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. | Q54955566 | ||
| Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome | Q58095881 | ||
| Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use | Q58608395 | ||
| Complement-mediated thrombotic microangiopathy associated with lupus nephritis | Q58727886 | ||
| Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary? | Q60044372 | ||
| Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1 | Q60943310 | ||
| Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count | Q68565309 | ||
| Complement c3a and c5a induce different signal transduction cascades in endothelial cells | Q74583305 | ||
| Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor | Q77587533 | ||
| Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation | Q80252186 | ||
| low body mass index is an independent risk factor for transplant-associated microangiopathy following total-body irradiation-based conditioning regimens | Q81817471 | ||
| Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation | Q83931969 | ||
| Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft | Q84145395 | ||
| Eculizumab cessation in atypical hemolytic uremic syndrome | Q87968695 | ||
| Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells | Q88101871 | ||
| C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension | Q88954754 | ||
| Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance | Q89357690 | ||
| Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome | Q89366026 | ||
| Haemolytic uraemic syndrome | Q89373702 | ||
| Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria | Q90390392 | ||
| Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance | Q90435254 | ||
| Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H | Q90602294 | ||
| Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation | Q90771508 | ||
| Emerging role of C5a/C5aR IL-17A axis in cGVHD | Q90860842 | ||
| Endothelium structure and function in kidney health and disease | Q90871287 | ||
| Safety profile after prolonged C3 inhibition | Q91456777 | ||
| Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy | Q91805694 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HELLP syndrome | Q1563513 |
| thrombotic microangiopathy | Q3312044 | ||
| Complement inhibitors | Q56883896 | ||
| disease susceptibility | Q65534164 | ||
| body constitution | Q66771588 | ||
| complement system proteins | Q67999591 | ||
| P304 | page(s) | 337 | |
| P577 | publication date | 2019-02-27 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics | |
| P478 | volume | 10 |
Search more.